Skip to search formSkip to main contentSkip to account menu

DAB389 epidermal growth factor

Known as: DAB389 EGF, DAB389-EGF, DAB389EGF 
A recombinant fusion protein composed of the diphtheria toxin with the receptor-binding domain replaced by human epidermal growth factor (EGF). When… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Epidermal Growth Factor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Inhibition of Protein Synthesis in Small Cell Lung Cancer Cells Induced by the Diphtheria Toxin-related Fusion Protein DAB 389 GRP '
DAB@ GRP Is composed of the catalytic and transmembrane domains ofdlphtheria toxin fused to gastrin-releasing peptide (GRP). DAB… 
Highly Cited
2005
Highly Cited
2005
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
PURPOSE The novel fusion protein, DAB389EGF, composed of the catalytic and translocation domains of diphtheria toxin (DAB389… 
Review
2003
Review
2003
DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.
Primary brain tumors including anaplastic astrocytomas and glioblastoma multiforme are difficult to treat because of their… 
2003
2003
Combination Fusion Protein Therapy of Refractory Brain Tumors: Demonstration of Efficacy in Cell Culture
Primary brain tumors including anaplastic astrocytomas and glioblastoma multiforme are difficult to treat because of their… 
Highly Cited
2002
Highly Cited
2002
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
PURPOSE Patients with relapsed or refractory acute myeloid leukemia have a poor prognosis. We tested the safety and efficacy of a… 
1997
1997
Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389 GRP.
DAB389 GRP is composed of the catalytic and transmembrane domains of diphtheria toxin fused to gastrin-releasing peptide (GRP… 
1996
1996
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
PURPOSE The epidermal growth factor receptor (EGF-R) is overexpressed frequently in breast cancer and other solid tumors… 
Review
1995
Review
1995
Targeting diphtheria toxin to growth factor receptors.
Biochemical, genetic and X-ray crystallographic analysis of diphtheria toxin have demonstrated that the native toxin is composed… 
Review
1995
Review
1995
Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies.
The results from the phase I/II studies of the intravenous administration of DAB486-IL-2 to patients with refractory… 
Highly Cited
1991
Highly Cited
1991
Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)